Pregnancy and Fetal Outcomes Following Exposure to Modafinil and Armodafinil During Pregnancy

Sigal Kaplan; Debra L Braverman; Ilana Frishman; Netta Bartov

doi:10.1001/jamainternmed.2020.4009

Pregnancy and Fetal Outcomes Following Exposure to Modafinil and Armodafinil During Pregnancy

JAMA Intern Med. 2021 Feb 1;181(2):275-277. doi: 10.1001/jamainternmed.2020.4009.

Authors

Sigal Kaplan¹, Debra L Braverman¹, Ilana Frishman¹, Netta Bartov¹

Affiliation

¹ Teva Pharmaceutical Industries Ltd, Netanya, Israel.

Abstract

This cohort study uses data from the US Provigil/Nuvigil Pregnancy Registry to assess prevalence of fetal major congenital malformations after exposure to modafinil and armodafinil during pregnancy.

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

Abnormalities, Drug-Induced / epidemiology*
Female
Humans
Modafinil / adverse effects*
Narcolepsy / drug therapy
Pregnancy
Registries
United States / epidemiology
Wakefulness-Promoting Agents / adverse effects*

Substances

Wakefulness-Promoting Agents
Modafinil